Nicholas Co. Inc. WI Takes Position in Merck & Co., Inc. (MRK)

Nicholas Co. Inc. WI purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 477,372 shares of the company’s stock, valued at approximately $28,102,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Blume Capital Management Inc. raised its position in shares of Merck & Co. by 14.0% in the third quarter. Blume Capital Management Inc. now owns 1,710 shares of the company’s stock worth $107,000 after buying an additional 210 shares during the last quarter. Roble Belko & Company Inc raised its stake in Merck & Co. by 16.6% in the third quarter. Roble Belko & Company Inc now owns 2,102 shares of the company’s stock worth $131,000 after buying an additional 300 shares during the last quarter. NewSquare Capital LLC raised its stake in Merck & Co. by 3.9% in the third quarter. NewSquare Capital LLC now owns 2,187 shares of the company’s stock worth $137,000 after buying an additional 83 shares during the last quarter. Mascoma Wealth Management LLC acquired a new stake in Merck & Co. during the fourth quarter worth $135,000. Finally, Cascade Investment Advisors Inc. acquired a new stake in Merck & Co. during the fourth quarter worth $135,000. Institutional investors and hedge funds own 74.10% of the company’s stock.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Shares of Merck & Co., Inc. (NYSE:MRK) traded down 0.983% during trading on Friday, reaching $61.935. 8,354,533 shares of the company’s stock were exchanged. Merck & Co., Inc. has a 52 week low of $53.06 and a 52 week high of $66.80. The stock has a 50 day moving average price of $63.91 and a 200-day moving average price of $62.49. The stock has a market capitalization of $170.05 billion, a price-to-earnings ratio of 43.926 and a beta of 0.79.

Merck & Co. (NYSE:MRK) last posted its earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.89. Merck & Co. had a return on equity of 24.08% and a net margin of 14.30%. The firm earned $10.10 billion during the quarter, compared to analyst estimates of $10.22 billion. During the same period in the previous year, the company earned $0.93 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Analysts predict that Merck & Co., Inc. will post $3.81 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 7th. Investors of record on Wednesday, March 15th were issued a $0.47 dividend. The ex-dividend date was Monday, March 13th. This represents a $1.88 annualized dividend and a yield of 3.01%. Merck & Co.’s dividend payout ratio (DPR) is currently 92.61%.

TRADEMARK VIOLATION NOTICE: “Nicholas Co. Inc. WI Takes Position in Merck & Co., Inc. (MRK)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/04/21/477372-shares-in-merck-co-inc-mrk-acquired-by-nicholas-co-inc-wi-updated-updated.html.

A number of analysts have recently weighed in on MRK shares. Vetr lowered shares of Merck & Co. from a “sell” rating to a “strong sell” rating and set a $52.27 price objective on the stock. in a research note on Tuesday, December 27th. Bryan, Garnier & Co initiated coverage on shares of Merck & Co. in a research note on Friday, January 13th. They issued a “buy” rating on the stock. Leerink Swann restated a “market perform” rating on shares of Merck & Co. in a research report on Monday, March 20th. JPMorgan Chase & Co. restated a “buy” rating on shares of Merck & Co. in a research report on Wednesday, January 11th. Finally, Cowen and Company restated a “market perform” rating and set a $68.00 price target on shares of Merck & Co. in a research report on Tuesday, April 11th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $67.74.

In related news, EVP Adam H. Schechter sold 53,850 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $63.48, for a total value of $3,418,398.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas R. Cech sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $63.42, for a total value of $317,100.00. Following the completion of the sale, the director now owns 5,100 shares of the company’s stock, valued at $323,442. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 160,809 shares of company stock valued at $10,261,846. Corporate insiders own 0.05% of the company’s stock.

About Merck & Co.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply